Alzheimer’s disease is notorious for robbing individuals of memory and cognitive function. Researchers have struggled for ...

There's still so much we don't know about Alzheimer's disease, but the link between poor sleep and worsening disease is one ...

which has just completed enrolment in a phase III trial of a tau-targeting drug in mild-to-moderate AD. Despite an R&D spend of around $15bn, a total of 20 beta amyloid protein-targeting drugs ...

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from ...

Researchers have developed a blood test based on a protein biomarker for tau tangles that can help diagnose Alzheimer’s ...

Delve into how the biotech industry is pivoting from the amyloid hypothesis to find new Alzheimer's disease treatments.

A study published in Brain Communications revealed new insights into early detection of Alzheimer’s disease. Researchers have ...

A recent study revealed that an experimental blood test for Alzheimer’s disease not only can help in accurate diagnosis but ...

Alzheimer’s is thought to be driven by the aggregation of two types of proteins, tau and amyloid beta. “It is anticipated that drugs targeting amyloid beta aggregates, considered an initiating ...

Biomarker and cognitive data supported treatment with the anti-amyloid agent lecanemab (Leqembi) for up to 36 months in early ...

The EMA has recommended refusing marketing authorization for donanemab, a monoclonal antibody against amyloid beta, in the ...

The researchers have been testing amyloid-removing therapies ... with sticky plaques made from beta amyloid proteins and toxic tangles made of a protein called tau. They theorized that removing ...